Ecolab (ECL)
(Delayed Data from NYSE)
$253.55 USD
-1.78 (-0.70%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $253.42 -0.13 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$253.55 USD
-1.78 (-0.70%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $253.42 -0.13 (-0.05%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth A Momentum C VGM
Zacks News
Ecolab (ECL) Q2 Earnings Beat Estimates
by Zacks Equity Research
Ecolab (ECL) delivered earnings and revenue surprises of 1.20% and 1.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Can These 3 Medical Device Stocks Hit Earnings This Season?
by Zacks Equity Research
Medical Device companies' quarterly results are likely to reflect strength in customer demand. Let's see how ECL, SYK and FMS are placed ahead of their earnings releases.
Countdown to Ecolab (ECL) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Get a deeper insight into the potential performance of Ecolab (ECL) for the quarter ended June 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Factors Setting the Tone for Ecolab's (ECL) Q2 Earnings
by Zacks Equity Research
Ecolab's (ECL) second-quarter results are likely to reflect continued segmental strength.
What's in Store for Materials ETFs in Q2 Earnings?
by Sweta Killa
Going into the Q2 earnings season, earnings releases from the sector giants will determine the movement of these funds.
Suzano (SUZ) to Buy 2 Mills From Pactiv Evergreen for $110M
by Zacks Equity Research
Suzano (SUZ) signs an agreement with Pactiv Evergreen to acquire two of its US industrial facilities.
Is Invesco Water Resources ETF (PHO) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PHO
Should You Invest in the Invesco Water Resources ETF (PHO)?
by Zacks Equity Research
Sector ETF report for PHO
Barrick (GOLD) Announces Strategic Plans for Loulo-Gounkoto
by Zacks Equity Research
Barrick (GOLD) emphasizes the importance of sustaining the Loulo-Gounkoto gold mining complex, with a significant economic contribution to Mali.
3 Reasons Why You Should Hold Avantor (AVTR) Stock for Now
by Zacks Equity Research
Avantor's (AVTR) strong product portfolio raises optimism about the stock.
Orthofix Medical's (OFIX) Fitbone System Gets FDA Clearance
by Zacks Equity Research
Orthofix Medical (OFIX) announces the FDA clearance and first U.S. implant of the Fitbone Transport and Lengthening System, used to treat large bone defects in the femur and tibia.
Masimo (MASI) Preliminary Q2 Results Aided by Healthcare Unit
by Zacks Equity Research
Masimo's (MASI) second-quarter 2024 results are likely to reflect the strength in the Healthcare business.
Inspire Medical (INSP) Dips on FDA Recall of IPG Model 3028
by Zacks Equity Research
The recall of Inspire Medical 's (INSP) Inspire IV Implantable Pulse Generators might dampen the company's future sales.
Royal Gold (RGLD) Issues Stream Segment Sales Update for Q2
by Zacks Equity Research
Royal Gold (RGLD) sells 52,600 gold equivalent ounces in the June-end quarter of 2024.
DuPont (DD) Tyvek Richmond Facility Gets ISCC+ Certification
by Zacks Equity Research
DuPont's (DD) global integration of ISCC PLUS certification into Tyvek production coincides with the company's commitment to empowering clients on their road to net zero emissions.
Stryker (SYK) Gains 11.6% YTD: What's Driving the Stock?
by Zacks Equity Research
Styker's (SYK) flagship Mako Total Knee Platform and a diversified product portfolio raise optimism about the stock.
Here's Why You Should Add H.B. Fuller (FUL) to Your Portfolio
by Zacks Equity Research
H.B. Fuller (FUL) presents a substantial investment opportunity with robust earnings outperformance and promising growth prospects.
ArcelorMittal (MT)-Partners Begin Carbon Capture Trial in Ghent
by Zacks Equity Research
ArcelorMittal (MT), MHI and D-CRBN are trialing plasma technology at Gent to convert CO2 into carbon monoxide for steel and chemical production, aiming to reduce emissions.
BASF (BASFY) Expands Sodium Methylate Capacity in South America
by Zacks Equity Research
This capacity increase is another step in BASF's (BASFY) business expansion for sodium methylate in South America, demonstrating the company's commitment to its customers and the South American biodiesel market.
Yara (YARIY) and Scatec Ink Renewable Ammonia Offtake Deal
by Zacks Equity Research
This project will bolster Yara's (YARIY) renewable ammonia sourcing portfolio and allow it to reliably serve its customers across several markets.
Baxter (BAX) Recovers After Life2000 Ventilation Systems Recall
by Zacks Equity Research
Baxter (BAX) recalls Life2000 ventilators due to damaged battery charger dongles, posing a risk of device failure
Hawkins (HWKN) Strengthens Water Treatment With Wofford Buy
by Zacks Equity Research
Hawkins (HWKN) acquires Wofford Water Service, strengthening its presence in the southern U.S. and expanding its Water Treatment business in Mississippi.
Smith & Nephew's (SNN) 5% Stake Acquired by Cevian Capital
by Zacks Equity Research
Smith & Nephew (SNN) eyes future growth as Cevian Capital purchases a 5% stake in the company.
Sandstorm Gold (SAND) Posts Y/Y Preliminary Q2 Revenue Decline
by Zacks Equity Research
Sandstorm Gold's (SAND) preliminary revenues fall 16.9% year over year, while the cash operating margin improves 17.1% in the second quarter.
Reasons to Retain Fresenius Medical (FMS) in Your Portfolio Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.